Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more
Porton Fine Chemicals Ltd (300363) - Net Assets
Latest net assets as of September 2025: CN¥5.49 Billion CNY
Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has net assets worth CN¥5.49 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.58 Billion) and total liabilities (CN¥3.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.49 Billion |
| % of Total Assets | 64.01% |
| Annual Growth Rate | 32.26% |
| 5-Year Change | 59.47% |
| 10-Year Change | 358.76% |
| Growth Volatility | 36.75 |
Porton Fine Chemicals Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Porton Fine Chemicals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Porton Fine Chemicals Ltd (2009–2024)
The table below shows the annual net assets of Porton Fine Chemicals Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.41 Billion | -11.29% |
| 2023-12-31 | CN¥6.10 Billion | -5.75% |
| 2022-12-31 | CN¥6.47 Billion | +54.61% |
| 2021-12-31 | CN¥4.19 Billion | +23.37% |
| 2020-12-31 | CN¥3.39 Billion | +10.73% |
| 2019-12-31 | CN¥3.06 Billion | +6.28% |
| 2018-12-31 | CN¥2.88 Billion | +98.95% |
| 2017-12-31 | CN¥1.45 Billion | +5.78% |
| 2016-12-31 | CN¥1.37 Billion | +16.15% |
| 2015-12-31 | CN¥1.18 Billion | +34.89% |
| 2014-12-31 | CN¥874.42 Million | +104.10% |
| 2013-12-31 | CN¥428.43 Million | +30.71% |
| 2012-12-31 | CN¥327.76 Million | +33.23% |
| 2011-12-31 | CN¥246.01 Million | +50.73% |
| 2010-12-31 | CN¥163.21 Million | +100.02% |
| 2009-12-31 | CN¥81.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Porton Fine Chemicals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 248496658570.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.47 Billion | 47.51% |
| Common Stock | CN¥545.46 Million | 10.49% |
| Other Components | CN¥2.18 Billion | 42.00% |
| Total Equity | CN¥5.20 Billion | 100.00% |
Porton Fine Chemicals Ltd Competitors by Market Cap
The table below lists competitors of Porton Fine Chemicals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Fenglong Electric Co Ltd Class A
SHE:002931
|
$900.63 Million |
|
Pharvaris BV
NASDAQ:PHVS
|
$901.02 Million |
|
Guangzhou Development Group Inc
SHG:600098
|
$902.01 Million |
|
Huaku Development Co Ltd
TW:2548
|
$902.07 Million |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
$900.19 Million |
|
Hubei TKD Crystal Electn
SHG:603738
|
$900.08 Million |
|
Changzheng Engineering Co Ltd
SHG:603698
|
$899.67 Million |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
$899.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Porton Fine Chemicals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,800,732,704 to 5,198,043,040, a change of -602,689,664 (-10.4%).
- Net loss of 287,753,293 reduced equity.
- Dividend payments of 301,499,554 reduced retained earnings.
- Share repurchases of 9,867,894 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-287.75 Million | -5.54% |
| Dividends Paid | CN¥301.50 Million | -5.8% |
| Share Repurchases | CN¥9.87 Million | -0.19% |
| Other Changes | CN¥-3.57 Million | -0.07% |
| Total Change | CN¥- | -10.39% |
Book Value vs Market Value Analysis
This analysis compares Porton Fine Chemicals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 71.32x to 2.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.30 | CN¥21.13 | x |
| 2010-12-31 | CN¥0.55 | CN¥21.13 | x |
| 2011-12-31 | CN¥0.69 | CN¥21.13 | x |
| 2012-12-31 | CN¥0.91 | CN¥21.13 | x |
| 2013-12-31 | CN¥1.19 | CN¥21.13 | x |
| 2014-12-31 | CN¥2.07 | CN¥21.13 | x |
| 2015-12-31 | CN¥2.74 | CN¥21.13 | x |
| 2016-12-31 | CN¥3.00 | CN¥21.13 | x |
| 2017-12-31 | CN¥3.20 | CN¥21.13 | x |
| 2018-12-31 | CN¥6.02 | CN¥21.13 | x |
| 2019-12-31 | CN¥5.74 | CN¥21.13 | x |
| 2020-12-31 | CN¥6.35 | CN¥21.13 | x |
| 2021-12-31 | CN¥7.43 | CN¥21.13 | x |
| 2022-12-31 | CN¥11.05 | CN¥21.13 | x |
| 2023-12-31 | CN¥10.65 | CN¥21.13 | x |
| 2024-12-31 | CN¥9.57 | CN¥21.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Porton Fine Chemicals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.55%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.70x
- Recent ROE (-5.54%) is below the historical average (15.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 38.70% | 10.48% | 0.95x | 3.90x | CN¥22.42 Million |
| 2010 | 26.21% | 9.44% | 0.99x | 2.80x | CN¥26.62 Million |
| 2011 | 25.21% | 11.29% | 0.96x | 2.32x | CN¥37.64 Million |
| 2012 | 24.44% | 11.64% | 0.87x | 2.41x | CN¥47.43 Million |
| 2013 | 23.38% | 13.64% | 0.77x | 2.21x | CN¥57.35 Million |
| 2014 | 15.48% | 12.71% | 0.53x | 2.29x | CN¥44.40 Million |
| 2015 | 9.86% | 10.81% | 0.43x | 2.13x | CN¥-1.55 Million |
| 2016 | 13.34% | 12.90% | 0.46x | 2.24x | CN¥42.84 Million |
| 2017 | 7.81% | 9.07% | 0.42x | 2.07x | CN¥-30.10 Million |
| 2018 | 4.32% | 10.51% | 0.27x | 1.52x | CN¥-163.82 Million |
| 2019 | 6.05% | 11.96% | 0.39x | 1.29x | CN¥-121.12 Million |
| 2020 | 9.57% | 15.66% | 0.46x | 1.33x | CN¥-14.73 Million |
| 2021 | 13.16% | 16.87% | 0.47x | 1.65x | CN¥125.76 Million |
| 2022 | 33.41% | 28.51% | 0.69x | 1.69x | CN¥1.41 Billion |
| 2023 | 4.60% | 7.28% | 0.39x | 1.62x | CN¥-313.21 Million |
| 2024 | -5.54% | -9.55% | 0.34x | 1.70x | CN¥-807.56 Million |
Industry Comparison
This section compares Porton Fine Chemicals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Porton Fine Chemicals Ltd (300363) | CN¥5.49 Billion | 38.70% | 0.56x | $900.30 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |